Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rhelion Life Sciences's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 65.13.
Rhelion Life Sciences's Days Inventory for the
three
months ended in Mar. 2026 was 193.78.
Rhelion Life Sciences's Days Payable for the
three
months ended in Mar. 2026 was 165.33.
Therefore, Rhelion Life Sciences's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 93.58.
Rhelion Life Sciences (STU:4YX0) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Rhelion Life Sciences Cash Conversion Cycle Related Terms
Rhelion Life Sciences Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Rhelion Life Sciences's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Rhelion Life Sciences's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rhelion Life Sciences Cash Conversion Cycle vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rhelion Life Sciences's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Rhelion Life Sciences's Cash Conversion Cycle falls into.
Rhelion Life Sciences Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Rhelion Life Sciences's Cash Conversion Cycle for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rhelion Life Sciences (STU:4YX0) has a Cash Conversion Cycle of 93.58 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Rhelion Life Sciences and its competitors.
Is Rhelion Life Sciences' Cash Conversion Cycle too high?
Rhelion Life Sciences' current Cash Conversion Cycle is 93.58. The Drug Manufacturers industry median Cash Conversion Cycle is 147.04. Rhelion Life Sciences' value of 93.58 is 36.4% below this industry median.
How does Rhelion Life Sciences' Cash Conversion Cycle compare to ZTS?
Rhelion Life Sciences' Cash Conversion Cycle of 93.58 can be compared against companies in the Drug Manufacturers industry. The industry median Cash Conversion Cycle is 147.04. Rhelion Life Sciences' value of 93.58 is 36.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Drug Manufacturers company?
The median Cash Conversion Cycle among Drug Manufacturers companies is 147.04, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rhelion Life Sciences's current Cash Conversion Cycle of 93.58 is 36.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Rhelion Life Sciences and its competitors. For the Drug Manufacturers industry, the median Cash Conversion Cycle is 147.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rhelion Life Sciences's current Cash Conversion Cycle is 93.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhelion Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Rhelion Life Sciences (STU:4YX0) is currently considered Possible Value Trap. The stock's GF Value™ is €0.01, compared to a current price of €0.01 — trading 30% below its estimated fair value. The current Cash Conversion Cycle is 93.58 and 36.4% below the Drug Manufacturers industry median of 147.04. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Rhelion Life Sciences (STU:4YX0), the current Cash Conversion Cycle is 93.58 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Red Light Holland Corp is engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands. Its products include Microdosing Kit and Merch. Its revenue is comprised of sales of wholesale truffles, cannabis seeds, and other cannabis products and sales of microdose packs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:4YX0 has been successfully added to your 
